logo
  

Evotec Reaches Licensing And Master Service Agreement With Kazia On Oncology

Evotec SE (EVTCY.PK,EVOTF.PK) said Monday that it reached a licensing and master service agreement with Kazia Therapeutics Limited (KZIA).

As per the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec's oncology project EVT801.

EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec's partnership with Sanofi.

Kazia seeks to clinically evaluate EVT801 both as a single agent and in combination with immunotherapy in a set of specific oncology indications. Evotec will manage the Phase I trial under the full sponsorship of Kazia.

Kazia will be responsible for any subsequent clinical evaluation and commercialisation of EVT801.

Evotec said it receives a small upfront payment as well as further payments for continued support progressing EVT801 into the clinic and beyond.

In addition, Evotec noted that it is eligible to receive clinical and commercial milestones of more than 300 million euros as well as tiered high single-digit royalties on the net sales of EVT801, which will be shared with Sanofi, Evotec's partner for the discovery and early development of EVT801.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hedge-fund billionaire William Ackman's Pershing Square Tontine Holdings Ltd. (PSTH) agreed to acquire 10% of Universal Music Group from French media conglomerate Vivendi (VIV.L, VIVEF.PK) for about $4 billion, the companies said in a statement on Sunday. The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings.
Follow RTT